Efficacy Of Irinotecan In Combination Research Articles

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment

The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status. We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts. Two hundred and twelve pts from 13 French centers were treated with at least one cycle of FOLFIRI (irinotecan 180 mg/m2 intravenous (i.v.) over 90 minutes on day 1 with folinic acid (FA) 400mg/m2 i.v. over two hours followed by 5-FU 400mg/m2 i.v. bolus then 5- FU 2400 mg/m2 continuous infusion over 46 hours on day 1, repeated every 14 days). Primary tumour sites were 120 (58%) stomach and 92 (42%) gastroesophageal junction. FOLFIRI was administered as first-line in 137 (65%) pts and as later-line in 75 (35%) pts for MGA. There was no difference between chemonaive and not chemonaive pts treated as firstline in terms of response rate 37% (95% CI: 25-50) vs 44% (95% CI: 21-69), median PFS, 6.7 (95% CI: 5.5-9.9) vs 5.3 months (95% CI: 3.6-6.9) (P = 0.25), and OS, 13.1 (95% CI: 11.7-18.7) vs 8.8 months (95% CI: 7.3—15.6) (P = 0.19), respectively. There was no difference between pts treated as second or later-line in terms of response rate 20% (95% CI: 8-39) vs 22% (95% CI: 6-48), median PFS, four months (95% CI: 2.8-5.4) vs 3.5 months (95% CI: 2.3-4.5) (P = 0.56), and OS, 10.4 months (95% CI: 5.4-14.4) vs 5.3 months (95% CI: 3.5-11.3) (P = 0.58), respectively. The global grade 3-4 toxicities were: diarrhea 11%, vomiting 9%, neutropenia 18%, febril neutropenia 4% (one toxic death). This retrospective study confirms the activity and good tolerance of FOLFIRI regimen in MGA as first-line as well as later-line.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) in metastatic gastric adenocarcinoma (MGA)

15539 Background: The most commonly used schedules for MGA are 5FU in combination with CDDP with or without Epirubicin (ECF) or Docetaxel (TCF). Irinotecan combined with 5FU (FOLFIRI regimen) was reported as active and well tolerated in a French randomized phase II study (Bouche, JCO 2004). The aim of this retrospective study was to evaluate the FOLFIRI regimen in a larger series of MGA patients (pts). Methods: Between 05/99 and 03/07, 219 pts from 13 French centers (162 males (72%), median age: 62 years, range: 25–88) were treated with at least one cycle of FOLFIRI. Primary tumour sites were 127 (58%) stomach and 92 (42%) gastroesophageal junction. The WHO status was 0 or 1 in 81% of pts and 95 (43%) pts were asymptomatic. One hundred forty two pts (65%) were treated in first- line (including 42 pts previously exposed to chemotherapy as (neo)adjuvant therapy). The 77 others pts (35%) received FOLFIRI as second- (n = 60) or later- (n=17) line for MGA. Results: Median number of chemotherapy cycles was 6 (r...